LONDON, December 19, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
On Wednesday, December 18, 2013, the U.S. equity market finished on a high note. The S&P 500 ended the day at 1,810.65, up 1.66%; the Dow Jones Industrial Average closed at 16,167.97, up 1.84%; and the NASDAQ Composite Index finished at 4,070.06, up 1.15%. The S&P 500 Health Care Sector Index rose 2.40% to close the session at 634.55; and the S&P 500 Biotechnology Industry Index surged 3.17% to close at 2,744.48. The S&P 500 Biotechnology Industry Index has gained 5.91% in the previous three months and 5.57% in the last one month, outperforming the S&P 500, which has gained 4.93% and 1.07% during the respective periods. Additionally, the S&P 500 Life Sciences Tools & Services Sub Industry Index closed the session 2.88% higher at 267.46. The major movers in the health care sector included XOMA Corp. (NASDAQ: XOMA), Celldex Therapeutics Inc. (NASDAQ: CLDX), Illumina Inc. (NASDAQ: ILMN), and Immunomedics Inc. (NASDAQ: IMMU). AAAResearchReports.com has released full comprehensive research on XOMA, CLDX, ILMN, and IMMU. These free technical analyses can be downloaded by signing up at:
XOMA Corp.'s stock rallied 6.61% on Wednesday, tracking gains in the US equity market. The company's shares finished the day at an intra-day high of $5.81, after oscillating between $5.45 and $5.81 during the trading session. A total of 1.81 million shares were traded, which is above the daily average volume of 1.71 million. The company's shares have rallied 26.86% in the previous three months and 48.97% in the last one month, outperforming the S&P 500, which has gained 4.93% and 1.07% during the respective periods. Furthermore, XOMA Corp.'s stock is trading near its 52-week high of $6.28 and also above its 50-day and 200-day moving averages of $4.71 and $4.23, respectively. Download free report on XOMA upon registration at:
Celldex Therapeutics Inc.'s stock ended the day 2.59% higher at $24.20, after fluctuating between $22.79 and $24.24 during Wednesday's trading session. A total of 2.12 million shares were traded, which is below the daily average volume of 3.16 million. The company's shares have gained 7.46% in the previous three trading sessions, outperforming the S&P 500, which has gained 1.99% during the same period. Additionally, Celldex Therapeutics Inc.'s stock is trading above its 200-day moving average of $19.66. CDLX technical report can be accessed for free by signing up at:
Shares in Illumina Inc. rose 2.57% on Wednesday, hitting a new 52-week high of $104.81. The company's shares closed the day at $104.62, after vacillating between $102.16 and $104.81 during the trading session. A total of 1.19 million shares were traded, which is above the daily average volume of 1.11 million. The company's shares have surged 25.67% in the previous three months and 13.59% in the last one month, outperforming the S&P 500, which has gained 4.93% and 1.07% during the respective periods. Moreover, Illumina Inc.'s stock is trading above its 50-day and 200-day moving averages of $93.14 and $76.02, respectively. The free report on ILMN can be downloaded by signing up now at:
On Wednesday, Immunomedics Inc.'s stock finished the day at $4.16, up 1.96% from the previous day's closing price of $4.08. The company's shares fluctuated between $4.00 and $4.17 during the trading session. A total of 0.46 million shares were traded, which is below the daily average volume of 1.22 million. The company's shares have advanced 5.58% in the previous three trading sessions and 16.20% in the last one month, outperforming the S&P 500, which has gained 1.99% and 1.07% during the respective periods. However, Immunomedics Inc.'s stock is trading below its 50-day and 200-day moving averages of $4.25 and $4.33, respectively. A free report on IMMU can be accessed by registering at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE AAA Research Reports